|
US9084784B2
(en)
|
2009-01-06 |
2015-07-21 |
Curelon Llc |
Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
EP3575288B1
(en)
|
2009-09-03 |
2021-10-27 |
Bristol-Myers Squibb Company |
Quinazolines as potassium ion channel inhibitors
|
|
US9511125B2
(en)
|
2009-10-21 |
2016-12-06 |
Curemark Llc |
Methods and compositions for the treatment of influenza
|
|
US8703941B2
(en)
|
2011-01-10 |
2014-04-22 |
Nimbus Iris, Inc. |
IRAK inhibitors and uses thereof
|
|
GB201114212D0
(en)
|
2011-08-18 |
2011-10-05 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2013068592A1
(en)
*
|
2011-11-10 |
2013-05-16 |
Fondation Jerome Lejeune |
Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide
|
|
AR090037A1
(es)
|
2011-11-15 |
2014-10-15 |
Xention Ltd |
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
|
|
BR112014017021A8
(pt)
|
2012-01-10 |
2017-07-04 |
Nimbus Iris Inc |
inibidores de irak e usos dos mesmos
|
|
EP2806875B1
(en)
*
|
2012-01-25 |
2017-07-19 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating compounds
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP2671575A1
(en)
*
|
2012-06-04 |
2013-12-11 |
Universität Regensburg |
Ras inhibitors
|
|
PT2858987T
(pt)
|
2012-06-11 |
2018-07-04 |
Bristol Myers Squibb Co |
Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida
|
|
IN2015DN00127A
(enExample)
|
2012-07-11 |
2015-05-29 |
Nimbus Iris Inc |
|
|
EP2872144A4
(en)
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
AU2013312477B2
(en)
*
|
2012-09-06 |
2018-05-31 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
MX372736B
(es)
*
|
2012-09-28 |
2020-06-19 |
Cancer Research Tech Ltd |
Inhibidores de azaquinazolina de la proteina quinasa c atipica.
|
|
GB201217704D0
(en)
*
|
2012-10-03 |
2012-11-14 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US20140136295A1
(en)
|
2012-11-13 |
2014-05-15 |
Apptio, Inc. |
Dynamic recommendations taken over time for reservations of information technology resources
|
|
CA2890911A1
(en)
|
2013-01-10 |
2014-07-17 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2956470A4
(en)
*
|
2013-02-15 |
2016-12-07 |
Univ Michigan Regents |
COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS
|
|
WO2014164543A1
(en)
|
2013-03-13 |
2014-10-09 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
CN104119343A
(zh)
*
|
2013-04-25 |
2014-10-29 |
苏州科捷生物医药有限公司 |
2-三氟甲基噻二唑类化合物及其用途
|
|
KR20160092991A
(ko)
|
2013-09-27 |
2016-08-05 |
님버스 아이리스 인코포레이티드 |
Irak 억제제 및 이의 용도
|
|
TWI648281B
(zh)
*
|
2013-10-17 |
2019-01-21 |
日商安斯泰來製藥股份有限公司 |
含硫二環式化合物
|
|
JP2017001954A
(ja)
*
|
2013-11-08 |
2017-01-05 |
石原産業株式会社 |
含窒素飽和複素環化合物
|
|
CN104892589A
(zh)
*
|
2014-03-07 |
2015-09-09 |
中国科学院上海药物研究所 |
一类杂环化合物、其制备方法和用途
|
|
WO2015136557A2
(en)
*
|
2014-03-11 |
2015-09-17 |
Godavari Biorefineries Limited |
Cancer stem cell targeting compounds
|
|
WO2016040330A1
(en)
*
|
2014-09-09 |
2016-03-17 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
WO2016081732A1
(en)
*
|
2014-11-19 |
2016-05-26 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
|
CN104592248A
(zh)
*
|
2014-12-31 |
2015-05-06 |
芜湖杨燕制药有限公司 |
一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法
|
|
AR104020A1
(es)
|
2015-06-04 |
2017-06-21 |
Kura Oncology Inc |
Métodos y composiciones para inhibir la interacción de menina con proteínas mill
|
|
HK1246593A1
(zh)
|
2015-06-04 |
2018-09-14 |
Kura Oncology, Inc. |
用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
EP4643952A3
(en)
|
2016-01-26 |
2026-01-14 |
Memorial Sloan Kettering Cancer Center |
Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
|
|
BR112018068703B1
(pt)
*
|
2016-03-16 |
2024-02-06 |
Kura Oncology, Inc. |
Inibidores substituídos de menin-mll e métodos de uso
|
|
KR102419524B1
(ko)
|
2016-03-16 |
2022-07-08 |
쿠라 온콜로지, 인크. |
메닌-mll의 가교된 이환식 억제제 및 사용 방법
|
|
WO2017192543A1
(en)
|
2016-05-02 |
2017-11-09 |
Regents Of The University Of Michigan |
Piperidines as menin inhibitors
|
|
WO2017207387A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
|
|
WO2018024602A1
(en)
|
2016-08-04 |
2018-02-08 |
Bayer Aktiengesellschaft |
2,7-diazaspiro[4.4]nonanes
|
|
ES2966316T3
(es)
|
2016-09-14 |
2024-04-19 |
Janssen Pharmaceutica Nv |
Inhibidores bicíclicos fusionados de interacción de MENIN-MLL
|
|
US12084462B2
(en)
|
2016-09-14 |
2024-09-10 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
BR112019004691A2
(pt)
*
|
2016-09-14 |
2019-06-25 |
Janssen Pharmaceutica Nv |
inibidores bicíclicos em espiro da interação menina-mll
|
|
WO2018050686A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
JP2019537585A
(ja)
|
2016-10-28 |
2019-12-26 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｅｚｈ２媒介性がんを治療するための組成物および方法
|
|
CA3045037A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
KR102513564B1
(ko)
*
|
2016-12-15 |
2023-03-22 |
얀센 파마슈티카 엔.브이. |
메닌-mll 상호작용의 아제판 억제제
|
|
EA201991448A1
(ru)
|
2017-01-06 |
2019-12-30 |
Янссен Фармацевтика Нв |
Азепановые ингибиторы взаимодействия менин-mll
|
|
EA038388B1
(ru)
*
|
2017-01-16 |
2021-08-19 |
Кура Онколоджи, Инк. |
Замещенные ингибиторы менина-mll и способы применения
|
|
US11944627B2
(en)
|
2017-03-24 |
2024-04-02 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and Ewing's sarcoma
|
|
CA3058448A1
(en)
|
2017-03-31 |
2018-10-04 |
The Regents Of The University Of Michigan |
Piperidines as covalent menin inhibitors
|
|
WO2018226976A1
(en)
|
2017-06-08 |
2018-12-13 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
WO2019060365A1
(en)
|
2017-09-20 |
2019-03-28 |
Kura Oncology, Inc. |
SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
|
|
WO2019120209A1
(en)
|
2017-12-20 |
2019-06-27 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-mll interaction
|
|
US11396517B1
(en)
|
2017-12-20 |
2022-07-26 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-MLL interaction
|
|
US11472799B2
(en)
|
2018-03-06 |
2022-10-18 |
Icahn School Of Medicine At Mount Sinai |
Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
|
|
US11325921B2
(en)
|
2018-03-30 |
2022-05-10 |
Sumitomo Dainippon Pharma Co., Ltd. |
Optically active crosslinked cyclic secondary amine derivative
|
|
JP2021527666A
(ja)
|
2018-06-21 |
2021-10-14 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
|
|
WO2020072391A1
(en)
|
2018-10-03 |
2020-04-09 |
The Regents Of The University Of Michigan |
Small molecule menin inhibitors
|
|
CN114423463B
(zh)
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
WO2021063346A1
(zh)
*
|
2019-09-30 |
2021-04-08 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
WO2021067215A1
(en)
|
2019-09-30 |
2021-04-08 |
Agios Pharmaceuticals, Inc. |
Piperidine compounds as menin inhibitors
|
|
CN118255773A
(zh)
|
2019-12-19 |
2024-06-28 |
詹森药业有限公司 |
取代的直链螺环衍生物
|
|
CN111297863B
(zh)
*
|
2020-03-30 |
2021-06-25 |
四川大学华西医院 |
menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
|
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
|
TW202204334A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20230391765A1
(en)
*
|
2020-10-21 |
2023-12-07 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of enl
|
|
CA3215379A1
(en)
|
2021-05-08 |
2022-11-17 |
Olivier Alexis Georges Querolle |
Substituted spiro derivatives
|
|
KR20240005747A
(ko)
|
2021-05-08 |
2024-01-12 |
얀센 파마슈티카 엔브이 |
치환된 스피로 유도체
|
|
JP2024521879A
(ja)
|
2021-06-01 |
2024-06-04 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体
|
|
BR112023025436A2
(pt)
|
2021-06-03 |
2024-02-27 |
Janssen Pharmaceutica Nv |
Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
|
|
JP2024525145A
(ja)
|
2021-06-17 |
2024-07-10 |
ヤンセン ファーマシューティカ エヌ．ベー． |
がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩
|
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
|
CN120529900A
(zh)
|
2022-11-24 |
2025-08-22 |
奥莱松基因组股份有限公司 |
用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
|